1/1
dw080422131.jpg
WASHINGTON, DC - April 22: House Energy Oversight and Investigations Subcommittee Chairman Bart Stupak, D-Mich., during the hearing with Food and Drug Administration Commissioner Andrew von Eschenbach. Accusing the Bush administration of being "too damn tight" to give the Food and Drug Administration the funding it needs to increase inspections of foreign manufacturers, House Energy and Commerce Committee Chairman John D. Dingell, D-Mich., Tuesday pressed the agency's commissioner Andrew von Eschenbach to tell Congress how much money the agency needs to put more inspectors in China and other countries. During the hearing before the House Energy and Commerce Oversight and Investigations Subcommittee, Dingell noted that while at least 80 percent of all active pharmaceutical ingredients are now imported, FDA is able to inspect only about 7 percent of the existing foreign firms shipping drugs each year to the U.S. "In other words, it would take FDA more than 30 years to inspect each Chinese firm a single time," assuming no new firms are added to the list of 700 now registered to export drug products to the U.S., Dingell said. FDA inspects U.S. based manufacturing plans about once every 2.7 years, he said. (Photo by Scott J. Ferrell/Congressional Quarterly)

WASHINGTON, DC - April 22: House Energy Oversight and Investigations Subcommittee Chairman Bart Stupak, D-Mich., during the hearing with Food and Drug Administration Commissioner Andrew von Eschenbach. Accusing the Bush administration of being "too damn tight" to give the Food and Drug Administration the funding it needs to increase inspections of foreign manufacturers, House Energy and Commerce Committee Chairman John D. Dingell, D-Mich., Tuesday pressed the agency's commissioner...
more »

Copyright Congressional Quarterly Inc.